---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027165"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-08-12T13:30:54+00:00"
generated_at: "2026-08-12T13:32:25.629070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Monopar Q2 net loss $5.3M; initiates rolling NDA for ALXN1840

## Summary
- Net loss $5.3M ($0.62/share) vs $2.5M ($0.35) in Q2 2025; R&D spend $4.77M (up from $1.73M).
- Cash and investments $134.3M as of June 30, 2026; runway through at least Dec 31, 2027.
- Rolling NDA submission to FDA for ALXN1840 initiated July 22, 2026; RPD designation granted June 30, 2026.
- RPD designation supports potential pediatric Priority Review Voucher at NDA approval; commercial team added.
- Positive Phase 3 FoCus data presented at EAN 2026 and AAN 2026 showing neurologic benefit vs standard of care.

## SEC filing metadata
- accession: 0001437749-26-027165
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-08-12T13:30:54+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/0001437749-26-027165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926027165/mnpr20260811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027165
- JSON: https://secwatch.observer/filing/0001437749-26-027165.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.